We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00548574
Recruitment Status : Completed
First Posted : October 24, 2007
Last Update Posted : March 5, 2015
Information provided by:

Study Description
Brief Summary:
The primary objective of the study was to compare the percentage of subjects in remission after 8 weeks of treatment with SPD476, 2.4 g/day once daily vs placebo and SPD476 4.8 g/day once daily versus placebo

Condition or disease Intervention/treatment Phase
Ulcerative Colitis Drug: SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine Drug: Mesalazine Phase 3

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 343 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Multi-Centre, Double-blind, Double Dummy, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to ASACOL 0.8g Three Times Daily, in Subjects With Mild to Moderate Ulcerative Colitis
Study Start Date : December 2003
Study Completion Date : July 2005

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Intervention Details:
    Drug: SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine
    Other Name: LIALDA
    Drug: Mesalazine
    Other Name: ASACOL

Outcome Measures

Primary Outcome Measures :
  1. Percentage of subjects in remission (UC-DAI score <=1, with scores of 0 for rectal bleeding and stool frequency and a sigmoidoscopy score reduction of 1 point or more from baseline) [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. Clinical improvement as defined by a drop of => 3 points from baseline in the overall UC-DAI score [ Time Frame: 8 weeks ]
  2. Change from baseine in UC-DAI score, symptoms, sigmoidscopy score, and PGA [ Time Frame: 8 weeks ]
  3. Clinical remission defined as subjects who scored 0 for both the total stool frequency and the total rectal bleeding score [ Time Frame: 8 weeks ]
  4. Treatment failure defined as unchanged, worsened missing or imcomplete UC-DAI score [ Time Frame: 8 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • newly diagnosed or relapsing mild to moderate UC (score of 4-10 (inclusive) on the UC-DAI scale, with a sigmoidoscopy score of => 1 and a PGA <=2) with compatible histology
  • females eligible if post--menopausal, surgically sterile or if they had a negative urine pregnancy test at screening and were on adequate contraception

Exclusion Criteria:

  • subjects with relapsing UC who were in relapse for > 6 weeks prior to baseline
  • subjects who relapsed on maintenace therapy with doses of mesalazine => 2g/day
  • subjects who had unsuccessfully treated their current relapse with steroids or a mesalazine dose of > 2g/day
  • subjects with Crohn's disease, proctitis, bleeding disorders, active peptic ulcer disease, previous colonic surgery, or those at an immediate risk of toxic megacolon or a stool culture positive for enteric pathogens
  • subjects who had used systemic or rectal steroids within the last 4 weeks, immunosuppressants wihtin the last 6 weeks or anti-inflammatory drugs on a repeat basis within 7 days prior to the baseline visit
  • subjects with hypersensitivity to salicylates and subjects with moderate/severe renal impairment
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00548574

Imelda General Hospital Dept of Gastroenterology
Bonheiden, Belgium
Sponsors and Collaborators
Principal Investigator: Professor Michael Kamm St Marks Hospital, London, UK
More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00548574     History of Changes
Other Study ID Numbers: SPD476-302
First Posted: October 24, 2007    Key Record Dates
Last Update Posted: March 5, 2015
Last Verified: November 2007

Additional relevant MeSH terms:
Colitis, Ulcerative
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents